Abstract. The radiological findings in 138 giant-cell tumours in 135 patients, with adequate clinical, radiological, and histological details, were studied. The purpose was to define the characteristic radiographic appearance of giant-cell tumour on presentation and after treatment and to assess whether radiological grading of the tumours was of value in determining prognosis. Most lesions were subarticular in location and eccentric to the long axis of the bone, had an ill-defined margin, and had eroded and expanded the overlying bony cortex. Half the lesions exceeded six cm in length along their long axis, contained a network of bony trabeculation, showed a linear periosteal reaction, and were accompanied by a soft-tissue mass. Rarely was the tumor margin sharply defined or was any sclerotic reaction evident in the adjacent bone. No individual radiological sign was of value in distinguishing tumours which would recur after treatment. However, lesions showing a combination of radiological signs suggesting slower growth did not recur.Postoperative resorption of a bone graft in the first year was observed several times in tumours which did not recur, whereas resorption of the graft after the first post-treatment year was usually associated with a recurrence of the tumour. Apparent consolidation of the lesion did not always denote healing. Recurrence in an apparently healed and consolidated lesion was not uncommon, particularly in the first two years after treatment. In a small group areas of radiolucency in an otherwise healed lesion persisted unchanged for many years.
Autoantibodies to oxidized low density lipoprotein have been shown to be an independent predictor of the progression of carotid atherosclerosis. This study examines the relationship between low density lipoprotein fatty acid composition and autoantibodies to both malondialdehyde‐modified and copper‐oxidized low density lipoprotein in non‐diabetic patients with (n = 17), and without (n = 18), definite evidence of previous myocardial infarction. The third group were non‐insulin‐dependent diabetic patients with no evidence of atherosclerosis (n = 15) and the fourth group were patients with non‐insulin‐dependent diabetes (n = 17) who had definite evidence of previous myocardial infarction. Fatty acids were measured by gas‐liquid chromatography. Antibodies to malondialdehyde‐modified low density lipoprotein and copper‐oxidized low density lipoprotein were determined by an ELISA method. Autoantibodies to copper‐oxidized low density lipoprotein were significantly higher in the non‐diabetic patients with heart disease when compared to any other group (p < 0.05). Autoantibodies to malondialdehyde‐modified low density lipoprotein were significantly higher in the non‐diabetic subjects with heart disease and in both diabetic groups compared to non‐diabetic subjects without coronary heart disease (p < 0.05). Lineolic acid (%) in low density lipoprotein did not differ between groups but arachidonic acid (%) was significantly lower in both diabetic and non‐diabetic patients with coronary heart disease (p < 0.05). The diabetic patients with low antibodies had 39.6 ± 2.2 % polyunsaturated fatty acids in their low density lipoprotein while diabetic patients with high antibodies had 46.7 ± 1.2 % polyunsaturates in their low density lipoprotein (p < 0.01). This study confirms the association between antibodies to oxidized low density lipoprotein and coronary heart disease and shows raised low density lipoprotein antibody levels in diabetic patients with and without demonstrable atherosclerosis. In the diabetic patients, those with high antibody levels had high polyunsaturated fatty acid levels in their LDL suggesting a possible role for dietary intervention. © 1997 John Wiley & Sons, Ltd.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.